The frequency and content of documentation for patients’ 131I therapies for checkpoint security agents: the final report of a national survey.

1250 Objectives Patients (pts) treated with I-131 for differentiated thyroid cancer (DTC) should receive documentation of their therapy (tx) to reduce inconveniences and travel delays. The objectives of this study were to determine the frequency and content of documentation of the pts9 I-131 tx for DTC and the frequency of the security agents (SAs) contacting a member of the treating team for verification. Methods Data were tabulated from a Thyroid Cancer Survivors’ Association, Inc.(ThyCa) survey emailed to ~15,000 associates of ThyCa and available online from Dec 2013 to Dec 2014. Responses were tabulated from the respondents who reported that they were >18 yo, had at least one tx of 131I for DTC, and were responding to their last 131I tx. Results Of 613 respondents, 440(72%) received a document stating that the pt had been administered an I-131 tx for DTC, 128(21%) had no document, and 45(7%) did not remember. Of 424 respondents recalling what was in their document, the following was included: pt’s name 356(84%), treating physician’s name 303(71%), a telephone number of a member of the treating team 275(65%), and the type, dose and date of radioiodine administered 325(77%), 280(66%), and 336(79%), respectively. Forty pts responded that the SAs requested further verification, which were: review of official document from the treating physician 24(60%), phone call to the hospital 3(7.5%), phone call to a member of the treating team 1(2.5%), request for fax of documentation 0(0%). Twelve (30%) pts had no verification. Conclusions Nearly 30% of pts treated with I-131 for DTC did not receive documentation of their I-131 tx. Of those who received a document, it was missing relevant information in 16-35%. In our view, every pt should receive a document noting at a minimum the pt’s name, date of birth, the name of treating physician, the telephone number of a member of the treating team, and the type, dose, and date of I-131 administration.